All News
Findings:
1. 21% of the patients in the Ankylosing Spondylitis Registry of Ireland (ASRI) were unemployed which is higher than their national average.
2. Stong predictors of unemployment were - Male sex and worse disease activity outcome measures(BASMI and ASQoL)
#ACR21 @RheumNow
swethaann23 swethaann23 ( View Tweet)
#ACR21 @RheumNow
Abst#0359 by Garrido-Cumbrera et al. has mapped out the journey from symptom onset to diagnosis of axSpA across 13 European countries.
swethaann23 swethaann23 ( View Tweet)
#ACR21 @RheumNow
Abst#0364 by Wetterslev et al. sought to identify axSpA characteristics of patients tapered off TNFI and showed clinical and radiographic improvement.
🔽52% were tapered off
⭐️The highest predictor of success is a low physician global VAS score
swethaann23 swethaann23 ( View Tweet)
Our recap of Day 2 of #ACR21 is now available on YouTube and the @RheumNow website, where you can find lots more videos, interviews and articles from the conference!
https://t.co/BxBXipxzif
@drdavidliew @doctorRBC @swethaann23 @MeralElRamahiMD
Mrinalini Dey DrMiniDey ( View Tweet)
⭐️AxSpA pts with decrease in oral microbial diversity
⭐️Immune response to oral/fecal microbes altered in AxSpA pts.
⭐️HLA-B27 associated ⬆️IgA coated microbes, may contribute to development of AxSpA
Abs#0052
https://t.co/NQgm0lpYJj
#ACR21
@RheumNow
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Preger report 9 novel aminoacyl tRNA synthetases in IIM patients. May these allow us to spare more patients biopsy? Abstr#0001 #ACR21 @RheumNow https://t.co/ikNXCEOeuj
Richard Conway RichardPAConway ( View Tweet)
Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are at⬆️risk of SARS-CoV-2 infection and⬆️mortality from COVID-19. Abstr#0086 #ACR21 @RheumNow #ACRBest https://t.co/B7tWs02gfc
Richard Conway RichardPAConway ( View Tweet)
Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz
Richard Conway RichardPAConway ( View Tweet)
Completely new one for me, Dr Taniguchi presenting on using ear ultrasound to diagnose and monitor disease activity in relapsing polychondritis. Appears useful, I suspect in clinical practice more so for diagnosis. Abstr#0169 #ACR21 @RheumNow https://t.co/PLJtkYkP3A
Richard Conway RichardPAConway ( View Tweet)
Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi
Richard Conway RichardPAConway ( View Tweet)
Dr McDermott @jeffsparks on risk factors for RA-bronchiectasis. Seropositivity, older age at RA onset, and lower BMI⬆️risk. Abstr#0288 #ACR21 @RheumNow https://t.co/7d2ZVWLzn6
Richard Conway RichardPAConway ( View Tweet)
Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ
Richard Conway RichardPAConway ( View Tweet)
Dr Adachi presents ⬆️BMD gain with denosumab than risedronate in RA. Non-significant reduction in fractures (very small numbers) Interesting, but need to see fracture benefit in larger study to justify dmab as first line Abstr#0445 #ACR21 @RheumNow https://t.co/GgaS9JZGzb
Richard Conway RichardPAConway ( View Tweet)
Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Richard Conway RichardPAConway ( View Tweet)
Diabetes puts you at risk of cardiovascular disease, right?
What about RA?
Look at this graph and compare the pair.
"already it was impossible to say which was which” - George Orwell, Animal Farm
#ACR21 ABST0287 @RheumNow https://t.co/r0yaeC530l https://t.co/mKJhoyJ2Cn
David Liew drdavidliew ( View Tweet)
Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX:
💠IFX-naive: improved disease activity
💠IFX-switched: maintained stable disease
💠No new safety concerns
https://t.co/VGBicnq15w
#ACR21 Abst#0817 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Small but important study of LN Class III, IV, and/or V with 6/18 pts considered complete responders by UProt (<500mg/g) continued to⬇️in renal fxn over 5 yrs. Bottom line: even dramatic ⬇️UProt does not tell the whole story.
https://t.co/51x4DlXkJC
#ACR21 Abst#1284 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Infxn risk of 1st year on rituximab for mod to severe SLE vs standard-of-care
🔹Most common SoC Rx: MMF, Aza, and/or cyclophosphamide
🔹🚫significant diff
🔹RTX pts = ⬆️dz duration, ⬆️# of prior meds, ⬇️maintenance steroid dose
https://t.co/AYQFXqlubl
#ACR21 Abst1288 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
SLE: Belimumab + standard rx significantly⬇️risk of severe flares vs placebo.
Greatest in those with:
🔹+dsDNA
🔹low C3 or C4
🔹SLICC/ACR Damage index of 0 (argument for early treatment!)
https://t.co/UcGXEklqwJ
#ACR21 Abst#1295
@RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Dr. Eric Ruderman gives his perspective on PsA data presented during the plenary session on Saturday at the #ACR21 annual meeting.
https://t.co/r9FgBO6VT7 https://t.co/JbV519XQoG
Links:
Dr. John Cush RheumNow ( View Tweet)
